Literature DB >> 8946194

Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas.

M Meddeb1, G Danglot, I Chudoba, A M Vénuat, J Bénard, H Avet-Loiseau, B Vasseur, D Le Paslier, M J Terrier-Lacombe, O Hartmann, A Bernheim.   

Abstract

Neuroblastoma shows remarkable heterogeneity, ranging from spontaneous regression to progression toward highly malignant tumors. In search of genetic abnormalities that could explain this variability, we have characterized neuroblastoma tumors by using multiple fluorescent hybridizations. Our results indicate that chromosome 17 is rearranged very frequently in the form of unbalanced translocations with numerous chromosomal partners, all leading to the presence of supernumerary copies of a 25 Mb chromosomal region originating from 17q23.1-qter. Additional 17q material was detected in more than 90% of untreated high-grade neuroblastomas and, along with 1p36 deletion, should represent the most frequent genetic abnormality of neuroblastoma observed until now.

Entities:  

Mesh:

Year:  1996        PMID: 8946194     DOI: 10.1002/(SICI)1098-2264(199611)17:3<156::AID-GCC3>3.0.CO;2-3

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  20 in total

Review 1.  Diagnosis and classification of the small round-cell tumors of childhood.

Authors:  S L Cohn
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 2.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

Authors:  J Mora; N K Cheung; B H Kushner; M P LaQuaglia; K Kramer; M Fazzari; G Heller; L Chen; W L Gerald
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

Review 4.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

5.  Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

Authors:  Robin M Hallett; Alex B K Seong; David R Kaplan; Meredith S Irwin
Journal:  Mol Oncol       Date:  2016-08-18       Impact factor: 6.603

Review 6.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

7.  In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei.

Authors:  A Valent; J Bénard; B Clausse; M Barrois; D Valteau-Couanet; M J Terrier-Lacombe; B Spengler; A Bernheim
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

8.  A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.

Authors:  Yosef Buganim; Ido Goldstein; Doron Lipson; Michael Milyavsky; Sylvie Polak-Charcon; Corine Mardoukh; Hilla Solomon; Eyal Kalo; Shalom Madar; Ran Brosh; Marina Perelman; Roy Navon; Naomi Goldfinger; Iris Barshack; Zohar Yakhini; Varda Rotter
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.

Authors:  Jean Bénard; Gilda Raguénez; Audrey Kauffmann; Alexander Valent; Hugues Ripoche; Virginie Joulin; Bastien Job; Gisèle Danglot; Sabrina Cantais; Thomas Robert; Marie-José Terrier-Lacombe; Agnès Chassevent; Serge Koscielny; Matthias Fischer; Frank Berthold; Marc Lipinski; Thomas Tursz; Philippe Dessen; Vladimir Lazar; Dominique Valteau-Couanet
Journal:  Mol Oncol       Date:  2008-07-23       Impact factor: 6.603

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.